-
Roche’s OCREVUS SC shows promise in Phase III multiple sclerosis trial
18 Apr 2024 16:55 GMT
… .
Furthermore, OCREVUS SC treatment led to quick and … Medicines Agency (EMA) and the US Food and Drug Administration (FDA) … potentially bring an additional treatment option to more … STARGLO trial where its Columvi (glofitamab) plus gemcitabine plus oxaliplatin …
-
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials
18 Apr 2024 07:34 GMT
… writing indicates that the trial is still recruiting.
… clinical trials that has promising preclinical data. The drug was … option in combination with oxaliplatin, 5-fluorouracil and … the only KRAS targeted treatments FDA approved in cancer. Specifically …
-
STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL
15 Apr 2024 17:10 GMT
… trial (NCT04408638) assessing glofitamab (Columvi) plus gemcitabine and oxaliplatin … ) plus gemcitabine and oxaliplatin. Safety remained consistent with … of treatment,” Levi Garraway, MD, PhD, chief medical officer … approval by the FDA for patients with …
-
Roche reports survival data for new dual-acting lymphoma drug
15 Apr 2024 17:24 GMT
… FDA’s gold standard for cancer treatment. In a separate trial … , lymphoma patients given the comparative therapy, Rituxan plus gemcitabine and oxaliplatin … drug, Epkinly, which has been evaluated across four late-stage trials … bispecific medicine called …
-
Roche’s Columvi offers survival benefit in Phase III DLBCL trial
15 Apr 2024 14:14 GMT
… STARGLO trial where its therapy Columvi (glofitamab) plus gemcitabine plus oxaliplatin ( … medicines.
Columvi has received accelerated approval from the US Food and Drug … treatment shortly after diagnosis.
Roche Global Product Development head and chief medical …
-
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
15 Apr 2024 13:09 GMT
… ) in combination with gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan … medicines.
Columvi was the first fixed-duration bispecific antibody to receive FDA … more prior treatments.
Earlier this year, Roche terminated two cancer drug deals …
-
Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma
17 Apr 2024 17:18 GMT
… . Recent randomized, controlled trials (RCTs) demonstrated improved … oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial … GEMOX and lenvatinib neoadjuvant treatment for resectable intrahepatic cholangiocarcinoma …
-
Roche Bispecific T-Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion
15 Apr 2024 15:16 GMT
… of two chemotherapy drugs, gemcitabine and oxaliplatin.
Overall survival … of the individual medicines without providing additional … earlier lines of treatment.
The FDA granted Roche accelerated … trial.
Nick Paul Taylor is a freelance pharmaceutical and biotech …
-
Genentech’s Columvi Meets Primary Endpoint in DLBCL
15 Apr 2024 14:03 GMT
… in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab … safety profiles of the individual medicines.
Columvi was the … the U.S. FDA and conditional marketing authorization … so patients can start treatment soon after diagnosis. This …
-
Roche’s Columvi passes Phase 3 lymphoma test as competition with AbbVie, Genmab continues
15 Apr 2024 10:45 GMT
… late-stage trial.
The CD20xCD3 bispecific antibody already won FDA accelerated … compared Columvi plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus … cell transplant. Columvi met the trial’s primary endpoint, achieving …